241 related articles for article (PubMed ID: 33580173)
1. Association of the plasma xanthine oxidoreductase activity with the metabolic parameters and vascular complications in patients with type 2 diabetes.
Okuyama T; Shirakawa J; Nakamura T; Murase T; Miyashita D; Inoue R; Kyohara M; Togashi Y; Terauchi Y
Sci Rep; 2021 Feb; 11(1):3768. PubMed ID: 33580173
[TBL] [Abstract][Full Text] [Related]
2. Annual change in plasma xanthine oxidoreductase activity is associated with changes in liver enzymes and body weight.
Furuhashi M; Koyama M; Matsumoto M; Murase T; Nakamura T; Higashiura Y; Tanaka M; Moniwa N; Ohnishi H; Saitoh S; Shimamoto K; Miura T
Endocr J; 2019 Sep; 66(9):777-786. PubMed ID: 31130575
[TBL] [Abstract][Full Text] [Related]
3. Independent association of plasma xanthine oxidoreductase activity with serum uric acid level based on stable isotope-labeled xanthine and liquid chromatography/triple quadrupole mass spectrometry: MedCity21 health examination registry.
Kurajoh M; Fukumoto S; Emoto M; Murase T; Nakamura T; Ishihara T; Go H; Yamamoto K; Nakatani S; Tsuda A; Yamada S; Morioka T; Mori K; Imanishi Y; Inaba M
Clin Chem Lab Med; 2020 Apr; 58(5):780-786. PubMed ID: 31085741
[TBL] [Abstract][Full Text] [Related]
4. Plasma Xanthine Oxidoreductase Activity as a Novel Biomarker of Metabolic Disorders in a General Population.
Furuhashi M; Matsumoto M; Tanaka M; Moniwa N; Murase T; Nakamura T; Ohnishi H; Saitoh S; Shimamoto K; Miura T
Circ J; 2018 Jun; 82(7):1892-1899. PubMed ID: 29643318
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of hypoxanthine and xanthine by obesity in a general population.
Furuhashi M; Koyama M; Higashiura Y; Murase T; Nakamura T; Matsumoto M; Sakai A; Ohnishi H; Tanaka M; Saitoh S; Moniwa N; Shimamoto K; Miura T
J Diabetes Investig; 2020 Jul; 11(4):878-887. PubMed ID: 31916414
[TBL] [Abstract][Full Text] [Related]
6. Xanthine oxidoreductase activity is associated with serum uric acid and glycemic control in hemodialysis patients.
Nakatani A; Nakatani S; Ishimura E; Murase T; Nakamura T; Sakura M; Tateishi Y; Tsuda A; Kurajoh M; Mori K; Emoto M; Inaba M
Sci Rep; 2017 Nov; 7(1):15416. PubMed ID: 29133805
[TBL] [Abstract][Full Text] [Related]
7. Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans.
Washio KW; Kusunoki Y; Murase T; Nakamura T; Osugi K; Ohigashi M; Sukenaga T; Ochi F; Matsuo T; Katsuno T; Moriwaki Y; Yamamoto T; Namba M; Koyama H
Metabolism; 2017 May; 70():51-56. PubMed ID: 28403945
[TBL] [Abstract][Full Text] [Related]
8. Plasma xanthine oxidoreductase activity in Japanese patients with type 2 diabetes across hospitalized treatment.
Kawachi Y; Fujishima Y; Nishizawa H; Nagao H; Nakamura T; Akari S; Murase T; Taya N; Omori K; Miyake A; Fukuda S; Takahara M; Kita S; Katakami N; Maeda N; Shimomura I
J Diabetes Investig; 2021 Aug; 12(8):1512-1520. PubMed ID: 33211396
[TBL] [Abstract][Full Text] [Related]
9. Association of Plasma Xanthine Oxidoreductase with Arterial Stiffness in Type 2 Diabetes with Liver Dysfunction.
Ohira M; Tanaka S; Watanabe Y; Nakamura S; Oka R; Yamaguchi T; Ban N; Saiki A; Ishihara N; Murano T; Murase T; Nakamura T; Tatsuno I
Am J Med Sci; 2022 Mar; 363(3):242-250. PubMed ID: 34619144
[TBL] [Abstract][Full Text] [Related]
10. Independent links between plasma xanthine oxidoreductase activity and levels of adipokines.
Furuhashi M; Matsumoto M; Murase T; Nakamura T; Higashiura Y; Koyama M; Tanaka M; Moniwa N; Ohnishi H; Saitoh S; Shimamoto K; Miura T
J Diabetes Investig; 2019 Jul; 10(4):1059-1067. PubMed ID: 30516339
[TBL] [Abstract][Full Text] [Related]
11. Xanthine oxidoreductase activity correlates with vascular endothelial dysfunction in patients with type 1 diabetes.
Washio K; Kusunoki Y; Tsunoda T; Osugi K; Ohigashi M; Murase T; Nakamura T; Matsuo T; Konishi K; Katsuno T; Namba M; Koyama H
Acta Diabetol; 2020 Jan; 57(1):31-39. PubMed ID: 31093763
[TBL] [Abstract][Full Text] [Related]
12. A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC/TQMS.
Murase T; Nampei M; Oka M; Miyachi A; Nakamura T
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Dec; 1039():51-58. PubMed ID: 27816314
[TBL] [Abstract][Full Text] [Related]
13. Unexpected high plasma xanthine oxidoreductase activity in female subjects with low levels of uric acid.
Furuhashi M; Mori K; Tanaka M; Maeda T; Matsumoto M; Murase T; Nakamura T; Koyama M; Moniwa N; Ohnishi H; Saitoh S; Shimamoto K; Miura T
Endocr J; 2018 Nov; 65(11):1083-1092. PubMed ID: 30068899
[TBL] [Abstract][Full Text] [Related]
14. Relationship between plasma xanthine oxidoreductase activity and left ventricular ejection fraction and hypertrophy among cardiac patients.
Fujimura Y; Yamauchi Y; Murase T; Nakamura T; Fujita SI; Fujisaka T; Ito T; Sohmiya K; Hoshiga M; Ishizaka N
PLoS One; 2017; 12(8):e0182699. PubMed ID: 28797123
[TBL] [Abstract][Full Text] [Related]
15. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
Furuhashi M
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E827-E834. PubMed ID: 32893671
[TBL] [Abstract][Full Text] [Related]
16. Increased plasma xanthine oxidoreductase activity deteriorates coronary artery spasm.
Watanabe K; Shishido T; Otaki Y; Watanabe T; Sugai T; Toshima T; Takahashi T; Yokoyama M; Kinoshita D; Murase T; Nakamura T; Wanezaki M; Tamura H; Nishiyama S; Takahashi H; Arimoto T; Yamauchi S; Yamanaka T; Miyamoto T; Kubota I; Watanabe M
Heart Vessels; 2019 Jan; 34(1):1-8. PubMed ID: 29936631
[TBL] [Abstract][Full Text] [Related]
17. The role of xanthine oxidoreductase and uric acid in metabolic syndrome.
Battelli MG; Bortolotti M; Polito L; Bolognesi A
Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2557-2565. PubMed ID: 29733945
[TBL] [Abstract][Full Text] [Related]
18. Independent association of plasma xanthine oxidoreductase activity with hypertension in nondiabetic subjects not using medication.
Furuhashi M; Higashiura Y; Koyama M; Tanaka M; Murase T; Nakamura T; Akari S; Sakai A; Mori K; Ohnishi H; Saitoh S; Shimamoto K; Miura T
Hypertens Res; 2021 Sep; 44(9):1213-1220. PubMed ID: 34117403
[TBL] [Abstract][Full Text] [Related]
19. Impact of Plasma Xanthine Oxidoreductase Activity on the Mechanisms of Distal Symmetric Polyneuropathy Development in Patients with Type 2 Diabetes.
Fujishiro M; Ishihara H; Ogawa K; Murase T; Nakamura T; Watanabe K; Sakoda H; Ono H; Yamamotoya T; Nakatsu Y; Asano T; Kushiyama A
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440256
[TBL] [Abstract][Full Text] [Related]
20. Plasma Xanthine Oxidoreductase Activity Associated with Glycemic Control in Patients with Pre-Dialysis Chronic Kidney Disease.
Nakatani S; Ishimura E; Murase T; Nakamura T; Nakatani A; Toi N; Nishide K; Uedono H; Tsuda A; Kurajoh M; Yamada S; Mori K; Inaba M; Emoto M
Kidney Blood Press Res; 2021; 46(4):475-483. PubMed ID: 34082427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
